Homepage > Rare diseases > Search

Search for a rare disease

*
(*) mandatory field

Riboflavin transporter deficiency

Suggest an update
Your message has been sent Your message has not been sent. Please contact an administrator.
Disease definition

A rare, genetic motor neuron disease characterized by a peripheral and cranial neuropathy, neuronal loss in anterior horns and atrophy of spinal sensory tracts, causing muscle weakness, sensory loss, diaphragmatic paralysis and respiratory insufficiency, and multiple cranial nerve deficits such as sensorineural hearing loss, bulbar symptoms, and loss of vision due to optic atrophy. Depending on the transporter affected, Riboflavin transporter deficiency 2 (RFVT2) and Riboflavin transporter deficiency 3 (RFVT3) are distinguished.

ORPHA:97229

Classification level: Disorder

Synonym(s):
  • Brown-Vialetto-van Laere syndrome

Prevalence: <1 / 1 000 000

Inheritance: Autosomal recessive

Age of onset: Adolescent, Adult, Childhood, Infancy

ICD-10: G12.2

ICD-11: LD2H.Y

OMIM: 211500 211530 614707

UMLS: C4551777

MeSH: C537111

GARD: 9993

MedDRA: 10084089

Summary
Epidemiology

Riboflavin transporter deficiency (RTD) has been reported in more than 100 genetically diagnosed cases to date.

Clinical description

Onset may occur from early infancy until adulthood, with a more severe presentation at a younger age. The most frequent presenting symptoms are cranial neuropathy, sensory ataxia, muscle weakness and respiratory insufficiency due to diaphragmatic paralysis. The cranial neuropathy leads to sensorineural hearing loss, loss of vision due to optic atrophy, dysarthria, dysphagia, feeding problems, facial weakness and eye movement impairments. Peripheral neuropathy in combination with anterior horn cell dysfunction and atrophy of the sensory tracts in the spinal cord causes muscle weakness with atrophy and (sensory) ataxia. Diaphragmatic paralysis in combination with general muscle weakness may rapidly lead to respiratory insufficiency, especially in infants and young children. Often, feeding through a nasogastric tube or gastrostomy device and artificial ventilation and tracheotomy are required. Sensory ataxia and optic atrophy seem more prevalent in RFVT2 than RFVT3 deficient patients.

Etiology

Pathogenic biallelic mutations in the genes SLC52A2 and SLC52A3 that encode riboflavin transporter 2 and 3 cause RTD2 and RTD3, respectively. Riboflavin (Vitamin B2) is a water-soluble vitamin that is essential for normal metabolism. The loss of function of the riboflavin transporter results in cellular flavin deficiency in different tissues. As flavins play an important role in mitochondrial function, mitochondrial dysfunction might act as a pathomechanism contributing to neurodegeneration in RTD.

Diagnostic methods

Diagnosis is only possible through mutational analysis of all genes coding for riboflavin transporters. Biochemical tests can show abnormalities such as abnormal (MADD-like) plasma acylcarnitine profiles, abnormal urine organic acids and decreased plasma flavin levels; however, approximately 50% of patients have normal results. Magnetic resonance imaging (MRI) is normal in the large majority of RTD patients. Electrophysiological testing (EMG) can show findings consistent with a sensorimotor axonal neuropathy with signs of anterior horn cell dysfunction, but normal results can also be observed.

Differential diagnosis

Differential diagnosis include neuromuscular diseases, in particular congenital or mitochondrial myopath and rapidly progressive neuropathies.

Antenatal diagnosis

Prenatal diagnosis is possible if family mutations in the SLC52A2 or SLC52A3 genes are known.

Genetic counseling

Transmission is autosomal recessive. Genetic counseling should be offered to at-risk couples (both individuals are carriers of a disease-causing mutation) informing them that there is a 25% risk of having an affected child at each pregnancy.

Management and treatment

Riboflavin supplementations is lifesaving and daily administration of a high dose oral riboflavin supplementation should be started immediately upon suspicion of RTD; treatment is lifelong. In cases with early onset, assisted ventilation, tracheostomy, and maintenance of nutrition via gastrostomy may be required. Regular clinical evaluation is required and includes neurological examination as well as evaluation of hearing and vision, respiratory function and skeletal deformities like scoliosis. Depending on the symptoms, physical and speech therapy should be initiated. Cochlear implants have proven highly successful for hearing loss in RTD.

Prognosis

If untreated, RTD is progressive and often fatal, with respiratory insufficiency as the main cause of death. However, severity and rate of progression vary between patients. When treated with high doses of riboflavin, the majority of patients show improvement over time and early treatment may even result in full recovery and normal development. In contrast, patients with irreversible damage may show stabilization but no improvement of symptoms. No deaths have been reported in riboflavin-treated patients.

Last update: February 2020 - Expert reviewer(s): Dr A.M. [Annet] BOSCH - Dr Eva HOYTEMA VAN KONIJNENBURG - Dr B. [Bregje] JAEGER
A summary on this disease is available in Français (2020) Español (2020) Deutsch (2020) Italiano (2020) Português (2008) Nederlands (2020) Polski (2013.pdf)
Detailed information
Guidelines
Clinical practice guidelines
Disease review articles
Review article
English (2012.pdf) - Orphanet J Rare Dis
Clinical genetics review
English (2021) - GeneReviews

Logo ERN: produced/endorsed by ERN(s) Logo FSMR: produced/endorsed by FSMR(s)

The documents contained in this website are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.